Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Piramal Pharma Limited ( (IN:PPLPHARMA) ).
Piramal Pharma reported a weak performance for the third quarter and first nine months of FY26, with consolidated revenue from operations declining 3% year-on-year in Q3 to ₹2,140 crore and 4% in the nine-month period to ₹6,117 crore, while EBITDA fell 32% in Q3 and 36% for the nine months, and the company swung to a net loss. The downturn was driven mainly by its CDMO segment, which saw double-digit revenue contraction amid inventory destocking for a large on-patent commercial product, slower early-stage order inflows linked to an uneven recovery in US biopharma funding, and regulatory delays affecting inhalation anesthesia sales from its Digwal facility, although CHG and consumer healthcare posted growth and cost-optimization efforts partly cushioned margins. Management pointed to early signs of recovery since October 2025, citing a pick-up in RFPs and order inflows on the back of improved US biopharma funding and M&A activity, continued outperformance of its consumer business, and ongoing US$90 million growth capex at its Lexington and Riverview sites, while expressing confidence in long-term prospects and reiterating that Q4 remains historically the strongest quarter for the company.
More about Piramal Pharma Limited
Piramal Pharma Limited is a leading global pharmaceutical, health and wellness company with operations spanning contract development and manufacturing (CDMO), complex hospital generics (CHG) and a consumer healthcare (PCH) portfolio. The group focuses on serving global biopharma clients, supplying specialty hospital products including inhalation anesthetics, and marketing power brands in consumer health across its key markets, while investing in capacity expansion and new product introductions to deepen its presence, particularly in ex-US geographies.
Average Trading Volume: 222,676
Technical Sentiment Signal: Sell
Current Market Cap: 201.2B INR
For detailed information about PPLPHARMA stock, go to TipRanks’ Stock Analysis page.